Nanostructured Natural Bioactives: A Promising Frontier for MASLD Therapy
Pharmaceuticals · 17.11.2026 · 19 (11) · 1832
DOI: 10.3390/ph19111832 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 17.11.2026. Verfasst von Xu-Ting Shen und 9 weiteren Autor:innen. Die Arbeit nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Siming Fund, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Science and Technology Development Program of Shanghai University of Traditional Chinese Medicine, Shanghai Oriental Talent Top-notch Program.
Abstract (Originalsprache)
Background
Natural bioactives derived from medicinal plants and dietary sources have long been used to manage metabolic and hepatic disorders. However, their application in metabolic dysfunction-associated steatotic liver disease (MASLD) is restricted by poor solubility, instability, low bioavailability, rapid metabolism, and insufficient hepatic exposure. This review evaluates the pharmacological mechanisms and therapeutic potential of nanostructured natural bioactives for MASLD.
Methods
Published preclinical and clinical evidence on natural bioactives and their nanostructured formulations for MASLD was narratively reviewed. Evidence was synthesized according to nanocarrier type, pharmacokinetic advantages, mechanisms of action, therapeutic outcomes, safety, and clinical translation.
Results
The included studies primarily covered three categories: nanostructured natural small-molecule bioactives, bioactive fractions, and single-source therapeutics. Small-molecule bioactives constituted the largest group, encompassing flavonoids, polyphenols, terpenoids, alkaloids, and lignans. Liposomes, nanoemulsions, polymeric nanoparticles, and micelles were the principal delivery platforms used to improve effective exposure through encapsulation, protection, and controlled release. Mechanisms included modulation of AMPK, SREBP-1c/FAS-, and PPARα/CPT-1-related lipid metabolism, suppression of NF-κB-associated inflammation, and enhancement of Nrf2-related antioxidant defenses, collectively attenuating hepatic lipid accumulation and injury. Nanostructured bioactive fractions and single-source therapeutics additionally involved multicomponent interactions, intestinal barrier protection, and gut–liver axis modulation. Nanostructured small-molecule bioactives showed translational promise, with oral nano-curcumin providing preliminary clinical evidence, although its additional benefits on hepatic fat content were inconsistent. Naturally derived vesicle-like nanoparticles also showed potential, but their compositional standardization, in vivo behavior, and long-term safety require further investigation.
Conclusions
Nanostructuring may improve the pharmacokinetic performance and pharmacological efficacy of natural bioactives against MASLD. Future studies should prioritize standardized formulation characterization, dose–exposure–response relationships, direct comparisons with free bioactives, long-term safety, and clinical trials.
Förderung
- The Siming Fund, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine
- Science and Technology Development Program of Shanghai University of Traditional Chinese Medicine
- Shanghai Oriental Talent Top-notch Program
- Shanghai Pudong New Area Health Commission
- Shuguang Hospital
Zitieren
APA
Shen, X., Sun, Q., Lin, R., Xin, X., Zou, C., Zeng, R., Shen, L., Geng, J., Feng, Q., & Shi, L. (2026). Nanostructured Natural Bioactives: A Promising Frontier for MASLD Therapy. Pharmaceuticals, 19(11), 1832. https://doi.org/10.3390/ph19111832
Vancouver
Shen X, Sun Q, Lin R, Xin X, Zou C, Zeng R, et al. Nanostructured Natural Bioactives: A Promising Frontier for MASLD Therapy. Pharmaceuticals. 2026;19(11):1832. doi:10.3390/ph19111832
BibTeX
@article{Shen2026,
author = {Shen, Xu-Ting and Sun, Qin-Mei and Lin, Ru-Tao and Xin, Xin and Zou, Chen and Zeng, Ren-Qiang and Shen, Li-Li and Geng, Jia and Feng, Qin and Shi, Lei},
title = {Nanostructured Natural Bioactives: A Promising Frontier for MASLD Therapy},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1832},
doi = {10.3390/ph19111832}
}
EUVIMED